206 related articles for article (PubMed ID: 16985955)
1. Innovative therapies for prostate cancer treatment.
Syed S; Tolcher A
Rev Urol; 2003; 5 Suppl 3(Suppl 3):S78-84. PubMed ID: 16985955
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for hormone-refractory prostate cancer.
Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD
Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249
[TBL] [Abstract][Full Text] [Related]
3. Newer therapies in advanced prostate cancer.
Hegeman RB; Liu G; Wilding G; McNeel DG
Clin Prostate Cancer; 2004 Dec; 3(3):150-6. PubMed ID: 15636681
[TBL] [Abstract][Full Text] [Related]
4. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group.
Winquist E; Waldron T; Berry S; Ernst DS; Hotte S; Lukka H
BMC Cancer; 2006 May; 6():112. PubMed ID: 16670021
[TBL] [Abstract][Full Text] [Related]
5. State-of-the-art treatment of metastatic hormone-refractory prostate cancer.
Goodin S; Rao KV; DiPaola RS
Oncologist; 2002; 7(4):360-70. PubMed ID: 12185298
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic options for hormone-refractory prostate cancer in 2007.
Hadaschik BA; Gleave ME
Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapeutic approaches for hormone-refractory prostate cancer.
Stavridi F; Karapanagiotou EM; Syrigos KN
Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
[TBL] [Abstract][Full Text] [Related]
8. Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC).
Papatsoris AG; Karamouzis MV; Papavassiliou AG
Curr Med Chem; 2005; 12(3):277-96. PubMed ID: 15723619
[TBL] [Abstract][Full Text] [Related]
9. Medical therapy of prostate cancer. A review.
Roscigno M; Sangalli M; Mazzoccoli B; Scattoni V; Da Pozzo L; Rigatti P
Minerva Urol Nefrol; 2005 Jun; 57(2):71-84. PubMed ID: 15951731
[TBL] [Abstract][Full Text] [Related]
10. [Taxanes in the chemotherapy of hormone-refractory prostate carcinoma].
Johannsen M; Wilke K; Schnorr D; Loening SA
Urologe A; 2004 Feb; 43(2):160-7. PubMed ID: 14991117
[TBL] [Abstract][Full Text] [Related]
11. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
Di Lorenzo G; De Placido S
Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
[TBL] [Abstract][Full Text] [Related]
12. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.
Gleave M; Miyake H
World J Urol; 2005 Feb; 23(1):38-46. PubMed ID: 15770517
[TBL] [Abstract][Full Text] [Related]
13. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
Berry W; Eisenberger M
Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
[TBL] [Abstract][Full Text] [Related]
14. Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer.
Chi KN
World J Urol; 2005 Feb; 23(1):33-7. PubMed ID: 15723221
[TBL] [Abstract][Full Text] [Related]
15. New strategies for the medical treatment of prostate cancer.
Isaacs JT
BJU Int; 2005 Dec; 96 Suppl 2():35-40. PubMed ID: 16359437
[TBL] [Abstract][Full Text] [Related]
16. Treatment options in hormone-refractory prostate cancer: current and future approaches.
Harris KA; Reese DM
Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129
[TBL] [Abstract][Full Text] [Related]
17. New therapeutic targets in the treatment of prostate cancer.
Vijjan V; Dubey D
Indian J Urol; 2007 Jan; 23(1):61-6. PubMed ID: 19675766
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of androgen-independent hormone refractory prostate cancer using docetaxel].
Miyoshi Y; Uemura H; Kubota Y
Nihon Rinsho; 2005 Feb; 63(2):298-302. PubMed ID: 15714982
[TBL] [Abstract][Full Text] [Related]
19. Satraplatin in the treatment of hormone-refractory metastatic prostate cancer.
Armstrong AJ; George DJ
Ther Clin Risk Manag; 2007 Oct; 3(5):877-83. PubMed ID: 18473011
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
Boehmer A; Anastasiadis AG; Feyerabend S; Nagele U; Kuczyk M; Schilling D; Corvin S; Merseburger AS; Stenzl A
Anticancer Res; 2005; 25(6C):4481-6. PubMed ID: 16334130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]